US20030013137A1 - Automated methods of detecting receptor activity - Google Patents
Automated methods of detecting receptor activity Download PDFInfo
- Publication number
- US20030013137A1 US20030013137A1 US10/095,620 US9562002A US2003013137A1 US 20030013137 A1 US20030013137 A1 US 20030013137A1 US 9562002 A US9562002 A US 9562002A US 2003013137 A1 US2003013137 A1 US 2003013137A1
- Authority
- US
- United States
- Prior art keywords
- intensity
- cell
- energy emitted
- detectable molecules
- gpcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 102000005962 receptors Human genes 0.000 title description 27
- 108020003175 receptors Proteins 0.000 title description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 138
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 130
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 130
- 102000003916 Arrestin Human genes 0.000 claims abstract description 66
- 108090000328 Arrestin Proteins 0.000 claims abstract description 66
- 239000000556 agonist Substances 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 25
- 210000003956 transport vesicle Anatomy 0.000 claims abstract description 25
- 230000004807 localization Effects 0.000 claims abstract description 14
- 210000001163 endosome Anatomy 0.000 claims abstract description 12
- 230000001268 conjugating effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 30
- 230000037361 pathway Effects 0.000 claims description 19
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 239000005090 green fluorescent protein Substances 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 22
- 210000004556 brain Anatomy 0.000 description 22
- 230000026731 phosphorylation Effects 0.000 description 21
- 238000006366 phosphorylation reaction Methods 0.000 description 21
- 238000001514 detection method Methods 0.000 description 16
- 230000002526 effect on cardiovascular system Effects 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 4
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 4
- 102100037346 Substance-P receptor Human genes 0.000 description 4
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 4
- 101710173688 Vasopressin V2 receptor Proteins 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000000955 neuroendocrine Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 102100029649 Beta-arrestin-1 Human genes 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010032969 beta-Arrestin 1 Proteins 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102400001103 Neurotensin Human genes 0.000 description 2
- 101800001814 Neurotensin Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010070503 PAR-2 Receptor Proteins 0.000 description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 2
- 101000728646 Rattus norvegicus Beta-arrestin-2 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108091008880 orphan GPCRs Proteins 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000021317 sensory perception Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 102100024402 Alpha-1B adrenergic receptor Human genes 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102000008081 Arrestins Human genes 0.000 description 1
- 108010074613 Arrestins Proteins 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102400000140 C5a anaphylatoxin Human genes 0.000 description 1
- 101800001654 C5a anaphylatoxin Proteins 0.000 description 1
- 102000004298 CX3C Chemokine Receptor 1 Human genes 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- -1 Calcitonin 1 Bone Chemical compound 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 101500007657 Crotalus durissus terrificus Crotoxin chain gamma Proteins 0.000 description 1
- 102100020802 D(1A) dopamine receptor Human genes 0.000 description 1
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 1
- 101710172165 D(2) dopamine receptor Proteins 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000003965 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 229940125499 GPCR antagonist Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102000001972 Galanin receptor 3 Human genes 0.000 description 1
- 108050009372 Galanin receptor 3 Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 102000052874 Gastrin receptors Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101710173663 Glucagon-1 Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 101000724725 Homo sapiens 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 description 1
- 101000689698 Homo sapiens Alpha-1B adrenergic receptor Proteins 0.000 description 1
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101000598887 Homo sapiens Olfactory receptor 6A2 Proteins 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102400001355 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100030874 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- 108010008409 Muscarinic M5 Receptor Proteins 0.000 description 1
- 102100035624 Muscarinic acetylcholine receptor M1 Human genes 0.000 description 1
- 108050007299 Muscarinic acetylcholine receptor M1 Proteins 0.000 description 1
- 102100036425 Muscarinic acetylcholine receptor M2 Human genes 0.000 description 1
- 108050006825 Muscarinic acetylcholine receptor M2 Proteins 0.000 description 1
- 102100036423 Muscarinic acetylcholine receptor M3 Human genes 0.000 description 1
- 108050008508 Muscarinic acetylcholine receptor M3 Proteins 0.000 description 1
- 102100025896 Muscarinic acetylcholine receptor M4 Human genes 0.000 description 1
- 108050008897 Muscarinic acetylcholine receptor M4 Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 1
- 102100035314 Neuromedin-U receptor 1 Human genes 0.000 description 1
- 101710098695 Neuromedin-U receptor 1 Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102400001111 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- 102100026700 Olfactory receptor 2C1 Human genes 0.000 description 1
- 101710139936 Olfactory receptor 2C1 Proteins 0.000 description 1
- 102100037776 Olfactory receptor 6A2 Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 102100032646 Opsin-5 Human genes 0.000 description 1
- 101710131039 Opsin-5 Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 101710125072 Phosrestin-2 Proteins 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102100022135 S-arrestin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 101710097909 Substance-P receptor Proteins 0.000 description 1
- 102100033009 Tachykinin-3 Human genes 0.000 description 1
- 101710149429 Tachykinin-3 Proteins 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000052301 human GNAZ Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003600 vasopressic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to methods of detecting G protein-coupled receptor (GPCR) activity in vitro and in vivo.
- GPCR G protein-coupled receptor
- the present invention provides methods for identifying compounds that activate the GPCR regulatory pathway and methods for identifying ligands of GPCRs.
- G protein-coupled receptors are cell surface proteins that translate hormone or ligand binding into intracellular signals. GPCRs are found in all animals, insects, and plants. GPCR signaling plays a pivotal role in regulating various physiological functions including phototransduction, olfaction, neurotransmission, vascular tone, cardiac output, digestion, pain, and fluid and electrolyte balance. Although they are involved in various physiological functions, GPCRs share a number of common structural features. They contain seven membrane domains bridged by alternating intracellular and extracellular loops and an intracellular carboxyl-terminal tail of variable length.
- GPCRs The magnitude of the physiological responses controlled by GPCRs is linked to the balance between GPCR signaling and signal termination.
- the signaling of GPCRs is controlled by a family of intracellular proteins called arresting.
- Arrestins bind activated GPCRs, including those that have been agonist-activated and especially those that have been phosphorylated by G protein-coupled receptor kinases (GRKs).
- GRKs G protein-coupled receptor kinases
- Receptors including GPCRs
- GPCRs have historically been targets for drug discovery and therapeutic agents because they bind ligands, hormones, and drugs with high specificity.
- GPCRs Although only several hundred human GPCRs are known, it is estimated that several thousand GPCRs exist in the human genome. Of these known GPCRs, many are orphan receptors that have yet to be associated with a function or ligands.
- One method of assaying GPCR activity uses a cell expressing a GPCR and a conjugate of an arrestin and a detectable molecule.
- a method of detecting G protein-coupled receptor (GPCR) pathway activity includes providing at least one cell that expresses a GPCR and a plurality of conjugated proteins. Each of the plurality of conjugated proteins is formed by conjugating an arrestin protein and a detectable molecule. The plurality of conjugated proteins are substantially evenly distributed in the cytoplasm of the at least one cell. A first image of the at least one cell is obtained by detecting an amount of energy emitted from the detectable molecules and storing a value relative to the amount of energy. The at least one cell is treated with a test compound. A second image of the at least one cell is obtained. The first image and the second image are compared to detect the localization of at least some of the plurality of conjugated proteins. The localization may occur at endocytic vesicles and/or endosomes.
- GPCR G protein-coupled receptor
- a method of detecting G protein-coupled receptor (GPCR) pathway activity whereby at least one cell that expresses a GPCR and a plurality of conjugated proteins are provided.
- Each of the plurality of conjugated proteins is formed by conjugating an arrestin protein and a detectable molecule.
- the plurality of conjugated proteins are substantially evenly distributed in the cytoplasm of the at least one cell.
- a first digital image of the at least one cell is obtained by detecting and measuring energy emitted from the detectable molecules.
- the first digital image is formed from an array of a plurality of pixels each having respective intensity values. A respective intensity value is based on the intensity of energy emitted from the detectable molecules associated with a pixel's location in the array.
- the at least one cell is treated with a test compound.
- a second digital image of the at least one cell is obtained by detecting and measuring energy emitted from the detectable molecules.
- the second digital image is formed from an array of a plurality of pixels each having respective intensity values.
- a respective intensity value is based on the intensity of energy emitted from the detectable molecules associated with a pixel's location in the array.
- the first digital image and the second digital image are compared to detect the localization of at least some of the plurality of conjugated proteins.
- the localization may occur at endocytic vesicles and/or endosomes.
- the localization of at least some of the plurality of conjugated proteins are detected by a change in apparent intensity of energy emitted from detectable molecules resulting in an increase in the value of at least some of the plurality of pixels.
- a method of detecting G protein-coupled receptor (GPCR) pathway activity is provided.
- At least one cell that expresses a GPCR and a plurality of conjugated proteins is provided.
- Each of the plurality of conjugated proteins is formed by conjugating an arrestin protein and a detectable molecule.
- the plurality of conjugated proteins are substantially evenly distributed in the cytoplasm of the at least one cell.
- the at least one cell is treated with a test compound.
- a digital image of the at least one cell is obtained by detecting and measuring energy emitted from the detectable molecules.
- the digital image is formed from an array of a plurality of pixels each having respective intensity values.
- a respective intensity value is based on the intensity of energy emitted from the detectable molecules associated with a pixel's location in the array.
- the localization of at least some of the plurality of conjugated proteins may be detected at endocytic vesicles and/or endosomes.
- the localization of at least some of the plurality of conjugated proteins is detected by a change in apparent intensity of energy emitted from detectable molecules resulting in a value of at least some of the plurality of pixels above a threshold intensity.
- FIG. 1 is a flow diagram of a method of detecting receptor activity in accordance with the invention
- FIG. 2 is a flow diagram of another method of detecting receptor activity in accordance with the invention.
- FIGS. 3 a and 3 b are confocal microscopic images of ⁇ arr-GFP fluorescence in cells stably expressing ⁇ arr-GFP fusion protein and the V2R (GPCR) of which:
- FIG. 3 a is before treatment with an agonist (Control)
- FIG. 3 b is after a 30 min. treatment with agonist at 37° C.
- FIGS. 4 a and 4 b are identical to FIGS. 3 a and 3 b , respectively, except that they were taken at a reduced detector sensitivity to prevent saturation of the detector;
- FIGS. 5 a and 5 b show confocal microscope images taken at reduced intensity with the pixels above the threshold intensity (here calculated as those within the >99th percentile) appearing as lightly shaded regions, of which:
- FIG. 5 a is of the control group
- FIG. 5 b is of the treated cells
- FIG. 6 is a histogram of pixel count vs pixel intensity
- FIG. 7 is a graph of the number of pixels above the threshold intensity for the control and treated cells.
- the methods offer the advantage of providing a gross comparison of the relative intensities of scans of cells before and after exposure to a test compound for a quick and simple determination of the activity of the test compound.
- test compounds include potential ligands, potential agonists, potential antagonists, and potential desensitization agents.
- the methods do not require qualitative analyzes of an image with respect to location of a detectable molecule and the detectable molecule's proximity to any specific cell structure.
- the method also does not require determinations of area of specific cell structures or any measurements within the cell nucleus. The methods will facilitate the rapid screening of compounds in an automated process.
- assays with which the methods may be used include, but are not limited to, those as described in U.S. Pat. Nos. 5,891,646 and 6,110,693, and U.S. application Ser. No. 09/993,844, filed Nov. 5, 2001, the disclosures of which are hereby incorporated by reference in their entirety.
- assays with which the methods may be used include, but are not limited to, assays using Fluorescent Resonance Energy Transfer (FRET) and assays using Bioluminescence Resonance Energy Transfer (BRET) technology as described in Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, “ ⁇ 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET),” Proc. Nat'l. Acad. Sci. USA 97, 7: 3684-3689.
- FRET Fluorescent Resonance Energy Transfer
- BRET Bioluminescence Resonance Energy Transfer
- G protein-coupled receptor kinases phosphorylate intracellular domains of GPCRs, for example, at the carboxyl-terminal tail.
- the carboxyl-terminal tail of many GPCRs begins shortly after the conserved NPXXY motif that marks the end of the seventh transmembrane domain (i.e. what follows the NPXXY motif is the carboxyl-terminal tail of the GPCR).
- the carboxyl-terminal tail may be relatively long (approximately tens to hundreds of amino acids), relatively short (approximately tens of amino acids), or virtually non-existent (less than approximately ten amino acids).
- “carboxyl-terminal tail” shall mean all three variants (whether relatively long, relatively short, or virtually non-existent).
- an arrestin protein associates with the GRK-phosphorylated receptor and uncouples the receptor from its cognate G protein.
- the term “arrestin” refers to all types of naturally occurring and engineered variants of arrestin, including, but not limited to, visual arrestin (sometimes referred to as Arrestin 1), ⁇ 3-arrestin 1 (sometimes referred to as Arrestin 2), and ⁇ -arrestin 2 (sometimes referred to as Arrestin 3).
- the interaction of the arrestin with the phosphorylated GPCR terminates GPCR signaling and produces a non-signaling, desensitized receptor.
- the arrestin bound to the desensitized GPCR targets the GPCR to clathrin-coated pits for endocytosis.
- the stability of the interaction of arrestin with the GPCR may dictate the rate of GPCR dephosphorylation, recycling, and resensitization.
- the GPCR/arrestin complex remains intact and is internalized into endosomes.
- an in vivo or in vitro environment may be utilized.
- a conjugate of an arrestin protein and a detectable molecule is utilized.
- detectable molecule means any molecule capable of detection by spectroscopic, photochemical, biochemical, immunochemical, electrical, radioactive, and optical means, including but not limited to, fluorescence, phosphorescence, and bioluminescence and radioactive decay.
- Detectable molecules include, but are not limited to, GFP, luciferase, ⁇ 3-galactosidase, rhodamine-conjugated antibody, and the like.
- Detectable molecules include radioisotopes, epitope tags, affinity labels, enzymes, fluorescent groups, chemiluminescent groups, and the like. Detectable molecules include molecules which are directly or indirectly detected as a function of their interaction with other molecule(s).
- GFP includes various naturally occurring forms of GFP that may be isolated from natural sources or genetically engineered, as well as artificially modified GFPs.
- GFPs are well known in the art. See, for example, U.S. Pat. Nos. 5,625,048; 5,777,079; and 6,066,476. It is well understood in the art that GFP is readily interchangeable with other fluorescent proteins, isolated from natural sources or genetically engineered, including, but not limited to, yellow fluorescent proteins (YFP), red fluorescent proteins (RFP), cyan fluorescent proteins (CFP), UV excitable fluorescent proteins, or any wave-length in between.
- YFP yellow fluorescent proteins
- RFP red fluorescent proteins
- CFP cyan fluorescent proteins
- UV excitable fluorescent proteins or any wave-length in between.
- the methods are designed to detect changes in the location of the conjugate of an arrestin protein and a detectable molecule after exposure of the cells to test compounds, test solutions, and test conditions.
- one or more cells that express a GPCR and that contain a conjugate of an arrestin protein and a detectable molecule are provided.
- Arrestin coupled to a detectable molecule may be detected and monitored.
- the location of the arrestin may be detected, for example, evenly distributed in the cell cytoplasm, concentrated at a cell membrane, and/or localized in endocytic vesicles.
- the proximity of arrestin to a GPCR may be monitored, as well as the proximity to any other cell structure.
- arrestin may be detected in proximity to GPCRs at a cell membrane and/or colocalized with a GPCR in endocytic vesicles.
- a substrate having deposited thereon one or more GPCRs having arrestin binding sites and agonist binding sites is provided, and a buffered solution comprising one or more conjugates of an arrestin protein and a detectable molecule is provided.
- the GPCR can be positioned on the substrate such that the arrestin binding sites are exposed to the arrestin and the agonist binding sites are accessible to agonists.
- the GPCR and arrestin may be obtained from whole cells and used in the in vitro assay after purification.
- the GPCR has arrestin binding sites and agonist binding sites and may be supported in a multilayer or bilayer lipid vesicle.
- the vesicle supporting the GPCR is deposited on the substrate, and the GPCR is supported in the lipid vesicle and deposited on the substrate such that the arrestin binding sites are exposed to arrestin and the receptor binding sites are accessible to agonists.
- the substrate may be any artificial substrate on which the modified GPCR may be deposited, including but not limited to, glass, plastic, diamond, ceramic, semiconductor, silica, fiber optic, biocompatible monomer, biocompatible polymer, polymer beads (including organic and inorganic polymers), and the like.
- the location of the arrestin may be detected and monitored in the in vitro environment.
- the redistribution of arrestin may be detected.
- arrestin in response to agonist stimulation, arrestin may be detected in proximity to GPCRs on the substrate, arrestin may be detected to compartmentalize, and the like.
- the method may be utilized with any membrane receptor protein in which agonist binding is linked to association of arrestin proteins.
- An illustrative, non-limiting list of known GPCRs with which the present invention may be used is contained in Table 1.
- the receptors are grouped according to classical divisions based on structural similarities and ligands.
- GPCRs that may be used in the present invention include known GPCRs, unknown or orphan GPCRs, and chimeric or modified GPCRs.
- a GPCR is considered to be an “unknown or orphan GPCR” if its function and/or ligands are unknown.
- Modified GPCRs include GPCRs that have one or more modifications in the carboxyl-terminal tail, modifications in the intracellular loop(s), and/or in the cytoplasmic end of the transmembrane region, preferably in the carboxyl-terminal tail.
- GPCRs for known receptors have been identified: Class A receptors, Class B receptors, and receptors with virtually non-existent carboxyl-terminal tails.
- the receptors are classified accordingly based on their interactions with and affinity for rat ⁇ 3-arrestin-2 in HEK-293 cells and may be predicted based on the amino acid residues in their carboxyl-terminal tail and the length of their carboxyl-terminal tail.
- a Class B receptor is a GPCR that has one or more sites of phosphorylation, preferably clusters of phosphorylation sites, properly positioned in its carboxyl-terminal tail such that it does recruit rat ⁇ -arrestin-2 to endosomes in HEK-293 cells under conditions as described in U.S. Pat. No. 5,891,646 and Oakley, et al. “Differential Affinities of Visual Arrestin, ⁇ Arrestin1, and ⁇ Arrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of Receptors,” Journal of Biological Chemistry, Vol 275, No. 22, pp 17201-17210, Jun. 2, 2000, the contents of which are hereby incorporated by reference in their entirety.
- a Class A receptor is a GPCR that does not have one or more sites of phosphorylation, preferably clusters of phosphorylation sites, properly positioned in its carboxyl-terminal tail such that it does not recruit rat ⁇ -arrestin-2 to endosomes in HEK-293 cells under conditions as described above for Class B receptors.
- Receptors with virtually non-existent carboxyl-terminal tails include, for example, olfactory and taste receptors.
- Table 2 is an illustrative, non-limiting list of known receptors, including the amino acid sequence for their carboxyl terminal tails and appropriate classification.
- Class B receptor examples the residues that may function as clusters of phosphorylation sites are shown in bolded italics.
- modified GPCRs are preferred.
- the modified GPCRs include GPCRs that have been modified to have one or more sites of phosphorylation, preferably clusters of phosphorylation sites, properly positioned in its carboxyl-terminal tail. These clusters of phosphorylation sites are preferably serine and threonine residues located in the carboxyl-terminal tail of the GPCR. These clusters are remarkably conserved in their position within the carboxyl-terminal tail domain and serve as primary sites of agonist-dependent phosphorylation.
- the clusters of amino acids may occupy two out of two, two out of three, three out of three, three out of four, four out of four, four out of five, five out of five, and the like consecutive amino acid positions. Accordingly, the clusters of amino acids that promote formation of a stable GPCR/arrestin complex are “clusters of phosphorylation sites.”
- the modified GPCRs containing one or more sites of phosphorylation, preferably clusters of phosphorylation sites, properly positioned in its carboxyl-terminal tail have an increased affinity for arrestin and colocalize with arrestin in endosomes after stimulation with agonist. These modified GPCRs recruit arrestin to endosomes within approximately 30 minutes of agonist stimulation.
- the one or more sites of phosphorylation, preferably clusters of phosphorylation sites must be optimally positioned within the GPCR tail for the GPCR to have an increased affinity for arrestin.
- the modified GPCRs may be constructed such that the one or more sites of phosphorylation, preferably clusters of phosphorylation sites, are optimally positioned within the carboxyl-terminal tail.
- the portions of polypeptides, which are to be fused together to form the modified GPCR are chosen such that the one or more sites of phosphorylation, preferably clusters of phosphorylation sites, are reliably positioned properly within the carboxyl-terminal tail.
- the location of discrete point mutations to create the modified GPCR may be chosen so that the one or more sites of phosphorylation, preferably clusters of phosphorylation sites, are properly positioned within the carboxyl-terminal tail.
- Cells useful in the present invention include eukaryotic and prokaryotic cells, including, but not limited to, bacterial cells, yeast cells, fungal cells, insect cells, nematode cells, plant cells, and animal cells.
- Suitable animal cells include, but are not limited to, HEK cells, HeLa cells, COS cells, U208 cells, and various primary mammalian cells.
- An animal model expressing a conjugate of an arrestin and a detectable molecule throughout its tissues or within a particular organ or tissue type, may be useful in studying cellular targets of known or unknown GPCR ligands.
- Cells useful in the present invention include those that express a known GPCR, a variety of known GPCRs, an unknown GPCRs, a variety of unknown GPCRs, a modified GPCR, a variety of modified GPCRs, and combinations thereof.
- a cell that expresses a GPCR is one that contains the GPCR as a functional receptor in its cell membrane.
- the cells may naturally express the GPCRs or may be genetically engineered to express the GPCRs. As one skilled in the art readily would understand, the cells may be genetically engineered to express GPCRs by molecular biological techniques standard in the genetic engineering art.
- a conjugate of an arrestin protein and a detectable molecule is utilized.
- All forms of arrestin both naturally occurring and engineered variants, including but not limited to, visual arrestin, ⁇ -arrestin 1 and ⁇ -arrestin 2, may be used in the present invention.
- the GPCRs of the present invention having enhanced affinity motifs in their carboxyl-terminal tails (naturally-occurring and modified) may interact to a detectable level with all forms of arrestin.
- Detectable molecules that may be used to conjugate with the arrestin include, but are not limited to, molecules that are detectable by spectroscopic, photochemical, radioactivity, biochemical, immunochemical, electrical, and optical means, including but not limited to, bioluminescence, phosphorescence, and fluorescence. These detectable molecules should be biologically compatible molecules and should not compromise the ability of the arrestin to interact with the GPCR system, and the interaction of the arrestin with the GPCR system must not compromise the ability of the detectable molecule to be detected.
- Preferred detectable molecules are optically detectable molecules, including optically detectable proteins, such that they may be excited chemically, mechanically, electrically, or radioactively to emit fluorescence, phosphorescence, or bioluminescence.
- Optically detectable molecules include, for example, beta-galactosidase, firefly luciferase, bacterial luciferase, fluorescein, Texas Red, and rhodamine-conjugated antibody. More preferred detectable molecules are inherently fluorescent molecules, such as fluorescent proteins, including, for example, Green Fluorescent Protein (GFP).
- GFP Green Fluorescent Protein
- the detectable molecule may be conjugated to the arrestin protein by methods as described in Barak et al. (U.S. Pat. Nos. 5,891,646 and 6,110,693).
- the detectable molecule may be conjugated to the arrestin at the front-end, at the back-end, or in the middle.
- the detectable molecules are molecules that are capable of being synthesized in the cell.
- the cell can be transfected with DNA so that the conjugate of arrestin and a detectable molecule is produced within the cell.
- cells may be genetically engineered to express the conjugate of arrestin and a detectable molecule by molecular biological techniques standard in the genetic engineering art.
- the methods of detection can be used to determine the distribution and/or location of the detectable molecules conjugated to the arrestin protein.
- the methods of detection may vary depending on the detectable molecule or molecules used.
- the methods of detection may be used to determine the intracellular location of the arrestin protein or interaction of the arrestin protein with a GPCR, for example, the concentration of arrestin at a cell membrane or the colocalization of arrestin protein with GPCR in an endocytic vesicle.
- GPCR for example, the concentration of arrestin at a cell membrane or the colocalization of arrestin protein with GPCR in an endocytic vesicle.
- One skilled in the art will readily be able to devise detection methods suitable for the detectable molecule or molecules used.
- the detectable molecules emit, reflect, and/or absorb energy depending on the detectable molecule used.
- the term “emit” is used in this specification, but should be interpreted to include “reflect” and “absorb” unless stated otherwise.
- the detector and method of detection used should be suitable for recognizing and recording the type of energy emitted.
- the detector utilized may image the cell point by point in series or in parallel, for example, using a single photodetector or a charge-coupled device array. Such configurations of detectors are known to the art.
- the detection methods may include using a detector for measuring the intensity of the energy emitted from the detectable molecules and may be operatively coupled to a computer controller for controlling the operation of the detector and performing an analysis of the signals received.
- the controller preferably includes a computer program product for performing analysis of the signals received from the detectors.
- the computer program product may be written specifically for use with the detection method or may be a commercially available program modified for use with the detection method.
- any optical method may be used where fluorescence, bioluminescence, or phosphorescence may be measured and recorded.
- one or more photodetectors for measuring fluorescence may be used and these photodetectors may be operatively coupled to a computer controller.
- a charge-coupled device array may also be used and may be operatively coupled to a computer controller.
- arrestin may be conjugated to GFP and the arrestin-GFP conjugate may be viewed by confocal microscopy.
- FIG. 1 is a flow diagram of a method of detecting receptor activity in accordance with one aspect of the invention.
- arrestin coupled to a detectable molecule may be detected evenly distributed in the cell cytoplasm.
- the detectable molecules emit energy, from which a first image may be generated.
- the cells are scanned according to the detection method utilized, and an image of the cells is generated.
- the image of the cells before treatment with an agonist will show the detectable molecules to be fairly evenly distributed in the cell cytoplasm.
- the intensity of energy emitted from the detectable molecules may be measured, converted to a digital format, and represented as pixels.
- the image may be mapped according to the position and intensity of each pixel.
- the pixels at a given intensity may be quantified and a mean intensity for the pixels may be calculated.
- the digitized image may be redisplayed on a video display.
- the cells are again scanned according to the detection method utilized, and a second image of the cells is generated.
- the second image of the cells can be converted to a digital image and analyzed as before.
- the sensitivity of the detector may be reduced in a number of ways, such as by using energy inhibiting filters at the detector or reducing the gain associated with the detector.
- the detectable molecules may be concentrated in specific, smaller areas instead of evenly distributed over the whole area of the cell cytoplasm. If the test compound is not an agonist, then the distribution of detectable molecules would be substantially unchanged.
- arrestin may be detected in proximity to GPCRs at a cell membrane and/or colocalized with a GPCR in endocytic vesicles. Since the detectable molecules are concentrated in smaller areas, the energy from the detectable molecules will be concentrated and of a significantly increased intensity. The apparent increase in intensity is due to a redistribution of the detectable molecules into smaller areas, and is not due to an inherent change in the intensity of the energy produced by each detectable molecule.
- the energy from detectable molecules concentrated in vesicles may be used to readily indicate activation of the GPCR pathway; therefore, positive and ready identification of these concentrations of detectable molecules is desirable.
- the detectable molecules evenly distributed in the cell cytoplasm give uniform, dilute energy emissions.
- the detectable molecules concentrated in endocytic vesicles give more intense energy emissions.
- FIG. 2 is a flow diagram of a method of detecting receptor activity in accordance with another aspect of the invention.
- a mean intensity can be obtained, and from this mean intensity, a threshold intensity can be set.
- the threshold intensity can be set such that it excludes energy emissions from detectable molecules evenly distributed in the cell cytoplasm (i.e., background emissions), but not energy emissions from detectable molecules colocalized in, for example, endocytic vesicles (i.e., target emissions).
- the threshold intensity may be, for example, the mean intensity of all energy emissions in a control cell (i.e., a cell not treated with an agonist) plus a determined number of standard deviations, such as two standard deviations (95th percentile) or three standard deviations (>99th percentile).
- the method of determining the threshold intensity is not controlling as long as the threshold is set to exclude as much of the background emissions as possible while permitting the detection of as much of the target emissions as possible.
- the first image may be taken of a control group of cells rather than the group of cells that are treated with the test compound. For example, once it is determined how much conjugated protein a particular cell line expresses, this information can be used to determine the mean intensity for the cell line. The mean intensity for the cell line can be used to set the threshold intensity in subsequent experiments.
- the energy emissions above the threshold intensity can be identified and quantified.
- the identified energy emissions may be tagged using a computer memory or the identified energy emissions may be marked in a computer generated image by changing the associated pixels to a unique color, for example, magenta.
- the computer generated image may be redisplayed on a video display after identifying (for example, by magenta) the portions of the image which have energy emissions at or above the threshold intensity.
- the pixels corresponding to energy emissions at or above the threshold intensity may be quantified by absolute number (i.e. they may be counted), as a percentage of the total number of pixels, or, preferably, as a weighted sum of pixels above the threshold intensity.
- the weights may be assigned in a variety of ways. For example, each pixel above the threshold intensity may be weighted according to its respective intensity value.
- the number of energy emissions above the threshold intensity may be used to determine whether and to what degree GPCRs have been activated. For example, a large number of energy emissions above the threshold may indicate activation.
- the number of energy emissions above the threshold intensity may also be used to determine whether and to what degree GPCRs have been deactivated. For example, very few energy emissions above the threshold may indicate deactivation.
- the number of energy emissions above the threshold intensity may be used to indicate activation in a variety of ways. For example, to indicate activation, a number or a percentage of energy emissions above the threshold may be set. If this set number or percentage is exceeded, it may be determined that the GPCR pathway has been activated. Further, the number of energy emissions above the threshold in the control (i.e., untreated) cells and treated cells may be compared and a number by which the treated cells' emissions exceed the control cells' emissions may be set. If this set number is exceeded, it may be determined that the GPCR pathway has been activated.
- one or more cells that express a GPCR and that contain a conjugate of an arrestin protein and a detectable molecule are provided.
- the cells are scanned according to the method of detection to generate an image of the cells based on the relative intensity of energy emissions from the detectable molecules.
- the image may be digitized and the relative intensity of energy emissions may be converted to pixel intensity values.
- activation or deactivation of the GPCR pathway may be detected. For example, a considerable amount of energy above a calculated threshold intensity may indicate activation of the GPCR pathway. Likewise, a significant decrease in the amount of energy above a calculated threshold intensity may indicate deactivation of the GPCR pathway.
- a mean intensity of the first image can be calculated, either directly from the first image or by analyzing the first array of pixels.
- a threshold intensity may be set to exclude energy emissions from detectable molecules evenly distributed in the cell cytoplasm but not energy emissions from detectable molecules in endocytic vesicles, for example, at two or three standard deviations above the mean intensity of the energy emissions in the first image (before exposure to the test compound or solution).
- the energy emissions above this threshold intensity may be identified and quantified.
- the associated pixels may be tagged using a computer memory or the pixels may be changed in a computer generated image to a unique color, for example, magenta.
- the image may be redisplayed on a video display after identifying (for example, by magenta) those pixels which are above the threshold intensity.
- the pixels above the threshold intensity may be quantified as a weighted sum.
- a comparison of the number of pixels above the threshold before and after exposure to the test compound or solution may be used to determine if the test compound or solution is or contains an agonist. If, for example, the test compound or solution is or contains an agonist, the number of pixels above the threshold after exposure to the agonist may dramatically increase.
- the automated methods of the present invention may also be used to screen test compounds and test solutions for GPCR antagonist activity.
- One or more cells that express a GPCR and that contain a conjugate of an arrestin protein and a detectable molecule are provided.
- the cells are scanned according to the method of detection to generate a first image of the cells.
- the cells are exposed to a test compound or test solution and then to a known agonist.
- the cells are scanned again according to the method of detection to generate a second image of the cells.
- the first and second images may be captured as or converted to first and second sets of pixels.
- the intensity of the first and second sets of pixels may be measured. As discussed above, the intensity of the first and second sets of pixels can be used to determine whether the GPCR pathway has been activated. For example, if the test compound is an antagonist, activation of the GPCR pathway would be blocked.
- a comparison of the number of signals above the threshold before and after exposure to the test compound or solution and the agonist may be used to determine if the test compound or solution is or contains an antagonist. If, for example, the test compound or solution is or contains an antagonist, then the number of energy emissions above the threshold before and after exposure to the agonist and test compound or solution may remain fairly constant instead of increasing as expected due to the agonist.
- Agonist mediated translocation of the ⁇ arr-GFP chimera from cell cytosol to endocytic vesicles was studied using a double stable cell line (stable for the ⁇ arr-GFP and the V2R), for example, HEK-293 cells or COS cells. These cells were transfected with plasmids containing cDNA for the V2R receptor and for the ⁇ arr-GFP conjugate.
- ⁇ arr-GFP was detected evenly distributed throughout the cytoplasm of cells expressing the V2R as indicated by the homogeneous ⁇ arr-GFP fluorescence in FIG. 3 a .
- Addition of arginine vasopressin (AVP, obtained from Sigma Chemicals, St. Louis, Mo.) promoted rapid redistribution of ⁇ arr-GFP from the cytoplasm to the receptor at the plasma membrane.
- a more prolonged exposure to the agonist i.e., after 30 min.
- ⁇ arr-GFP redistributed to endocytic vesicles (FIG. 3 b ).
- FIGS. 3 a and 3 b were taken at standard sensitivity and the intense energy emitted from detectable molecules localized in endocytic vesicles saturated the detector (i.e., when attempting to plot the intensities of the emissions captured as pixels, the intensities were off the scale).
- FIGS. 4 a and 4 b are identical to FIGS. 3 a and 3 b , respectively, except that they were taken at a reduced sensitivity to prevent saturation of the detector by ⁇ arr-GFP colocalized in endocytic vesicles.
- FIGS. 4 a and 4 b demonstrate that concentration of ⁇ arr-GFP in endocytic vesicles produces spots of fluorescent intensity much greater than the fluorescent intensity observed in the cytoplasm of the control cells.
- the threshold intensity was calculated as the mean cell intensity plus three standard deviations (>99th percentile). Pixels with intensities above the threshold were indicated in a magenta color in both the control and treated images (FIGS. 5A and 5 b , respectively).
- the control cells had very few magenta-colored pixels.
- the cells treated with agonist had many magenta-colored pixels.
- the magenta-colored pixels in the treated cells of FIG. 5 b closely correspond to the ⁇ arr-GFP containing endocytic vesicles in FIG. 4 b.
- FIG. 6 graphs the pixels in both the control cells and treated cells that are above the threshold.
- the first curve labeled Control Cell
- the second curve labeled Vesicles
- the threshold was set at the mean cell intensity of the control cells plus three standard deviations (>99th percentile).
- FIG. 7 is a graph of the number of pixels above the threshold intensity for the control and treated cells.
- the number of pixels above the threshold in the treated cells is approximately 120 times that of the control cells. This data readily may be used to indicate that an agonist was added and the ⁇ arr-GFP translocated to endocytic vesicles.
- alpha-2B-adrenergic receptor human.
- ACCESSION A37223 npviytifnqdfrrafrrilcrpwtqtaw
- alpha-2C-adrenergic receptor human.
- beta-1-adrenergic receptor Homo sapiens.
- dopamine receptor D1 [Homo sapiens]. ACCESSION NP — 000785 npiiyafnadfrkafstllgcyrlcpatnnaietvsinnngaamfsshheprgsiskecnlvyliphavgssedlkkeeaagiarple klspalsvildydtdvslekiqpitqngqhpt
- muscarinic acetylcholine receptor M2 [Homo sapiens]. ACCESSION NP — 000730 npacyalcnaffkkffkhllmchyknigatr
- muscarinic acetylcholine receptor M4 [Homo sapiens]. ACCESSION NP — 000732 npacyalcnaffkkffrhlllcqyrnigtar
- angiotensin receptor 1 [Homo sapiens].
- cx3c chemokine receptor 1 (cx3cr1) (fractalkine receptor) ACCESSION P49238 npliyafagekfrrylyhlygkclavlcgrsvhvdfsssesqrsrhgsvlssnftyhtsdgdallil
- SUBSTANCE-P RECEPTOR SPR
- NK-1 RECEPTOR NK-1 RECEPTOR
- vasopressin receptor type 2 [Homo sapiens].
- thyrotropin-releasing hormone receptor human. ACCESSION JN0708 npviynlmsqkfraafrklcnckqkptekpanysvalnysvikesdhfsteldditvtdtylsatkvsfddtclasevsfsqs
- neuromedin U receptor 1 [Homo sapiens]. ACCESSION AAG24793 npvlyslmssrfretfqealclgacchrlrprhsshslsrmttgstlcdvgslgswvhplagndgpeaqqetdps
- VPR vasopressive intestinal peptide receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/095,620 US20030013137A1 (en) | 2001-03-13 | 2002-03-12 | Automated methods of detecting receptor activity |
PCT/US2002/007434 WO2002073199A1 (en) | 2001-03-13 | 2002-03-13 | Automated methods of detecting receptor activity |
EP02717608A EP1386154A4 (en) | 2001-03-13 | 2002-03-13 | AUTOMATED DETECTION OF RECEPTOR ACTIVITY |
CA002440683A CA2440683A1 (en) | 2001-03-13 | 2002-03-13 | Automated methods of detecting receptor activity |
JP2002572410A JP2004532978A (ja) | 2001-03-13 | 2002-03-13 | 受容体活性を検出する自動化された方法 |
AU2002248597A AU2002248597B2 (en) | 2001-03-13 | 2002-03-13 | Automated methods of detecting receptor activity |
US10/629,176 US20040029190A1 (en) | 2001-03-13 | 2003-07-29 | Automated methods of detecting receptor activity |
US11/084,928 US7455982B2 (en) | 2001-03-13 | 2005-03-21 | Automated methods of detecting receptor activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27533901P | 2001-03-13 | 2001-03-13 | |
US10/095,620 US20030013137A1 (en) | 2001-03-13 | 2002-03-12 | Automated methods of detecting receptor activity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/629,176 Division US20040029190A1 (en) | 2001-03-13 | 2003-07-29 | Automated methods of detecting receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030013137A1 true US20030013137A1 (en) | 2003-01-16 |
Family
ID=26790404
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/095,620 Abandoned US20030013137A1 (en) | 2001-03-13 | 2002-03-12 | Automated methods of detecting receptor activity |
US10/629,176 Abandoned US20040029190A1 (en) | 2001-03-13 | 2003-07-29 | Automated methods of detecting receptor activity |
US11/084,928 Expired - Fee Related US7455982B2 (en) | 2001-03-13 | 2005-03-21 | Automated methods of detecting receptor activity |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/629,176 Abandoned US20040029190A1 (en) | 2001-03-13 | 2003-07-29 | Automated methods of detecting receptor activity |
US11/084,928 Expired - Fee Related US7455982B2 (en) | 2001-03-13 | 2005-03-21 | Automated methods of detecting receptor activity |
Country Status (6)
Country | Link |
---|---|
US (3) | US20030013137A1 (ja) |
EP (1) | EP1386154A4 (ja) |
JP (1) | JP2004532978A (ja) |
AU (1) | AU2002248597B2 (ja) |
CA (1) | CA2440683A1 (ja) |
WO (1) | WO2002073199A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040080A1 (en) * | 2001-08-16 | 2003-02-27 | Gero Miesenbock | Bio-synthetic photostimulators and methods of use |
US20040091946A1 (en) * | 2000-11-03 | 2004-05-13 | Oakley Robert H. | Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity |
US20050009111A1 (en) * | 2002-10-25 | 2005-01-13 | Loomis Carson R. | Methods of identifying reduced internalization transmembrane receptor agonists |
US20050032125A1 (en) * | 2002-05-13 | 2005-02-10 | Norak Biosciences, Inc. | Constitutively translocating cell line |
US20050100934A1 (en) * | 2003-07-09 | 2005-05-12 | Lee Kevin J. | Method for assaying protein-protein interaction |
US20050136431A1 (en) * | 2000-11-03 | 2005-06-23 | Oakley Robert H. | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
US20060173630A1 (en) * | 2004-12-09 | 2006-08-03 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US20090082410A1 (en) * | 2002-05-13 | 2009-03-26 | Molecular Devices Corporation | Constitutively translocating cell line |
US20160123919A1 (en) * | 2013-04-25 | 2016-05-05 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU782966B2 (en) | 1999-06-08 | 2005-09-15 | University Of Iowa Research Foundation, The | Compounds and methods to enhance RAAV transduction |
JP2006521825A (ja) * | 2003-03-31 | 2006-09-28 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | rAAV導入を高めるための化合物および方法 |
JP2007006830A (ja) * | 2005-07-01 | 2007-01-18 | Olympus Corp | 細胞内の顆粒状構造物の測定方法 |
WO2007127464A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Iowa Research Foundation | Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor |
CN101063657A (zh) | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 在活体细胞中筛选配体与受体结合的方法和系统 |
EP2422194B1 (en) | 2009-04-20 | 2014-12-17 | Agency For Science, Technology And Research | Vesicular system and uses thereof |
US9096889B2 (en) | 2011-11-23 | 2015-08-04 | Promega Corporation | Compositions and methods for monitoring transmembrane trafficking |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
CA3016985C (en) | 2016-03-07 | 2023-07-04 | University Of Iowa Research Foundation | Aav-mediated expression using a synthetic promoter and enhancer |
US11142775B2 (en) | 2017-01-13 | 2021-10-12 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5548661A (en) * | 1991-07-12 | 1996-08-20 | Price; Jeffrey H. | Operator independent image cytometer |
US5705335A (en) * | 1993-11-26 | 1998-01-06 | Hendry; Lawrence B. | Design of drugs involving receptor-ligand-DNA interactions |
US5770176A (en) * | 1995-12-08 | 1998-06-23 | Chiron Diagnostics Corporation | Assays for functional nuclear receptors |
US5854004A (en) * | 1991-11-25 | 1998-12-29 | Boehringer Ingleheim Gmbh | Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path |
US5864488A (en) * | 1994-02-24 | 1999-01-26 | University Court Of The University Of Glasgow | Three dimensional glycoprotein hormone structure representation using a computer |
US5874219A (en) * | 1995-06-07 | 1999-02-23 | Affymetrix, Inc. | Methods for concurrently processing multiple biological chip assays |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US5919646A (en) * | 1996-08-02 | 1999-07-06 | Axiom Biotechnologies, Inc. | Apparatus and method for real-time measurement of cellular response |
US5972629A (en) * | 1984-08-17 | 1999-10-26 | The Scripps Research Institute | Method for characterizing antigenic reactivity of biological sample |
US5972639A (en) * | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
US5987390A (en) * | 1997-10-28 | 1999-11-16 | Smithkline Beecham Corporation | Methods and systems for identification of protein classes |
US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US6017496A (en) * | 1995-06-07 | 2000-01-25 | Irori | Matrices with memories and uses thereof |
US6025129A (en) * | 1995-04-25 | 2000-02-15 | Irori | Remotely programmable matrices with memories and uses thereof |
US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
US6067114A (en) * | 1996-03-05 | 2000-05-23 | Eastman Kodak Company | Detecting compositional change in image |
US6100026A (en) * | 1995-04-25 | 2000-08-08 | Irori | Matrices with memories and uses thereof |
US6124102A (en) * | 1989-06-07 | 2000-09-26 | Affymetrix, Inc. | Methods for determining receptor-ligand binding using probe arrays |
US6127133A (en) * | 1991-12-20 | 2000-10-03 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein function using same |
US6199017B1 (en) * | 1995-03-17 | 2001-03-06 | Kureha Kagaku Kogyo Kabushiki Kaisha | Biochemical information processing apparatus, biochemical information processing method, and biochemical information recording medium |
US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
US6219622B1 (en) * | 1995-03-24 | 2001-04-17 | University Of Guelph | Computational method for designing chemical structures having common functional characteristics |
US6221612B1 (en) * | 1997-08-01 | 2001-04-24 | Aurora Biosciences Corporation | Photon reducing agents for use in fluorescence assays |
US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219335A (en) * | 1978-09-18 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Immunochemical testing using tagged reagents |
US4324633A (en) * | 1980-10-20 | 1982-04-13 | Lovejoy Curtis N | Electrolytic apparatus for treating continuous strip material |
US4908773A (en) * | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
US5324633A (en) * | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
US5912122A (en) * | 1993-06-04 | 1999-06-15 | Sibia Neurosciences, Inc. | Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6 |
US5521705A (en) * | 1994-05-12 | 1996-05-28 | Oldenbourg; Rudolf | Polarized light microscopy |
US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
DK1095277T3 (da) * | 1998-07-13 | 2003-04-22 | Cellomics Inc | System til cellebaseret screening |
-
2002
- 2002-03-12 US US10/095,620 patent/US20030013137A1/en not_active Abandoned
- 2002-03-13 CA CA002440683A patent/CA2440683A1/en not_active Abandoned
- 2002-03-13 AU AU2002248597A patent/AU2002248597B2/en not_active Expired
- 2002-03-13 EP EP02717608A patent/EP1386154A4/en not_active Withdrawn
- 2002-03-13 WO PCT/US2002/007434 patent/WO2002073199A1/en not_active Application Discontinuation
- 2002-03-13 JP JP2002572410A patent/JP2004532978A/ja active Pending
-
2003
- 2003-07-29 US US10/629,176 patent/US20040029190A1/en not_active Abandoned
-
2005
- 2005-03-21 US US11/084,928 patent/US7455982B2/en not_active Expired - Fee Related
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972629A (en) * | 1984-08-17 | 1999-10-26 | The Scripps Research Institute | Method for characterizing antigenic reactivity of biological sample |
US6124102A (en) * | 1989-06-07 | 2000-09-26 | Affymetrix, Inc. | Methods for determining receptor-ligand binding using probe arrays |
US5548661A (en) * | 1991-07-12 | 1996-08-20 | Price; Jeffrey H. | Operator independent image cytometer |
US5854004A (en) * | 1991-11-25 | 1998-12-29 | Boehringer Ingleheim Gmbh | Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path |
US6127133A (en) * | 1991-12-20 | 2000-10-03 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein function using same |
US5705335A (en) * | 1993-11-26 | 1998-01-06 | Hendry; Lawrence B. | Design of drugs involving receptor-ligand-DNA interactions |
US5864488A (en) * | 1994-02-24 | 1999-01-26 | University Court Of The University Of Glasgow | Three dimensional glycoprotein hormone structure representation using a computer |
US6199017B1 (en) * | 1995-03-17 | 2001-03-06 | Kureha Kagaku Kogyo Kabushiki Kaisha | Biochemical information processing apparatus, biochemical information processing method, and biochemical information recording medium |
US6219622B1 (en) * | 1995-03-24 | 2001-04-17 | University Of Guelph | Computational method for designing chemical structures having common functional characteristics |
US6100026A (en) * | 1995-04-25 | 2000-08-08 | Irori | Matrices with memories and uses thereof |
US6025129A (en) * | 1995-04-25 | 2000-02-15 | Irori | Remotely programmable matrices with memories and uses thereof |
US6017496A (en) * | 1995-06-07 | 2000-01-25 | Irori | Matrices with memories and uses thereof |
US5874219A (en) * | 1995-06-07 | 1999-02-23 | Affymetrix, Inc. | Methods for concurrently processing multiple biological chip assays |
US5770176A (en) * | 1995-12-08 | 1998-06-23 | Chiron Diagnostics Corporation | Assays for functional nuclear receptors |
US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
US6067114A (en) * | 1996-03-05 | 2000-05-23 | Eastman Kodak Company | Detecting compositional change in image |
US5919646A (en) * | 1996-08-02 | 1999-07-06 | Axiom Biotechnologies, Inc. | Apparatus and method for real-time measurement of cellular response |
US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US6110693A (en) * | 1997-06-05 | 2000-08-29 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US5972639A (en) * | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
US6221612B1 (en) * | 1997-08-01 | 2001-04-24 | Aurora Biosciences Corporation | Photon reducing agents for use in fluorescence assays |
US5987390A (en) * | 1997-10-28 | 1999-11-16 | Smithkline Beecham Corporation | Methods and systems for identification of protein classes |
US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091946A1 (en) * | 2000-11-03 | 2004-05-13 | Oakley Robert H. | Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity |
US20050136431A1 (en) * | 2000-11-03 | 2005-06-23 | Oakley Robert H. | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
US7144733B2 (en) * | 2001-08-16 | 2006-12-05 | Sloan-Kettering Institute For Cancer Research | Bio-synthetic photostimulators and methods of use |
US20030040080A1 (en) * | 2001-08-16 | 2003-02-27 | Gero Miesenbock | Bio-synthetic photostimulators and methods of use |
US20090082410A1 (en) * | 2002-05-13 | 2009-03-26 | Molecular Devices Corporation | Constitutively translocating cell line |
US20050032125A1 (en) * | 2002-05-13 | 2005-02-10 | Norak Biosciences, Inc. | Constitutively translocating cell line |
US20090081652A1 (en) * | 2002-05-13 | 2009-03-26 | Molecular Devices Corporation | Constitutively Translocating Cell Line |
US20060029983A1 (en) * | 2002-05-13 | 2006-02-09 | Oakley Robert H | Methods of screening compounds for GRK6 modulating activity |
US7332292B2 (en) | 2002-05-13 | 2008-02-19 | Molecular Devices Corporation | Constitutively translocating cell line |
US7297503B2 (en) | 2002-10-25 | 2007-11-20 | Molecular Devices Corporation | Methods of identifying reduced internalization transmembrane receptor agonists |
US20050009111A1 (en) * | 2002-10-25 | 2005-01-13 | Loomis Carson R. | Methods of identifying reduced internalization transmembrane receptor agonists |
US8017398B2 (en) | 2003-07-09 | 2011-09-13 | Life Technologies Corporation | Method for assaying protein-protein interaction |
US20060147975A1 (en) * | 2003-07-09 | 2006-07-06 | Lee Kevin J | Method for assaying protein-protein interaction |
US7049076B2 (en) | 2003-07-09 | 2006-05-23 | Sentigen Biosciences, Inc. | Method for assaying protein—protein interaction |
US20050100934A1 (en) * | 2003-07-09 | 2005-05-12 | Lee Kevin J. | Method for assaying protein-protein interaction |
US20110096976A1 (en) * | 2004-12-09 | 2011-04-28 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US20060173630A1 (en) * | 2004-12-09 | 2006-08-03 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US20110096977A1 (en) * | 2004-12-09 | 2011-04-28 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US7818130B2 (en) * | 2004-12-09 | 2010-10-19 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US8121383B2 (en) | 2004-12-09 | 2012-02-21 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US8649981B2 (en) | 2004-12-09 | 2014-02-11 | Cellomics, Inc. | Automated method and system for setting image analysis parameters to control image analysis operations |
US20160123919A1 (en) * | 2013-04-25 | 2016-05-05 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
US10809222B2 (en) * | 2013-04-25 | 2020-10-20 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
Also Published As
Publication number | Publication date |
---|---|
WO2002073199A1 (en) | 2002-09-19 |
AU2002248597B2 (en) | 2008-01-31 |
CA2440683A1 (en) | 2002-09-19 |
US20050181423A1 (en) | 2005-08-18 |
US7455982B2 (en) | 2008-11-25 |
JP2004532978A (ja) | 2004-10-28 |
US20040029190A1 (en) | 2004-02-12 |
EP1386154A1 (en) | 2004-02-04 |
EP1386154A4 (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7455982B2 (en) | Automated methods of detecting receptor activity | |
AU2002248597A1 (en) | Automated methods of detecting receptor activity | |
Kallal et al. | Using green fluorescent proteins to study G-protein-coupled receptor localization and trafficking | |
Eidne et al. | Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells | |
EP2073013B1 (en) | Method of identifying transmembrane protein-interacting compounds | |
US6893827B1 (en) | Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation | |
AU2003228956B2 (en) | Constitutively translocating cell line | |
US20090226949A1 (en) | Single-cell biosensor for the measurement of GPCR ligands in a test sample | |
JP2008514185A (ja) | Gタンパク質共役受容体およびそのシグナル伝達経路の断片相補アッセイ | |
US7163800B2 (en) | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity | |
Leifert et al. | G-protein-coupled receptors in drug discovery: nanosizing using cell-free technologies and molecular biology approaches | |
Adie et al. | CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells | |
US7297503B2 (en) | Methods of identifying reduced internalization transmembrane receptor agonists | |
Zhang et al. | Screening and characterization of G-protein–coupled receptor ligands for drug discovery | |
US20050136431A1 (en) | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity | |
Haji et al. | Single-cell Analysis of β2-Adrenergic Receptor Dynamics by Quantitative Fluorescence Microscopy | |
US20070196865A1 (en) | Methods Of Screening Compositions For G Protein-Coupled Receptors Aganist Agonists | |
Moreno et al. | Techniques for the study of GPCR heteromerization in living cells and animal models | |
Protein-Coupled et al. | 9 High Throughput | |
JP2004180668A (ja) | リガンドの決定方法 | |
VALLER et al. | By DOROTHEA HAASEN, ANDREAS SCHNAPP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DUKE UNIVERSITY, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARAK, LARRY S.;OAKLEY, ROBERT H.;REEL/FRAME:013033/0753;SIGNING DATES FROM 20020506 TO 20020510 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |